Attometrics Overview

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $149K

  • Investors
  • 3

Attometrics General Information


Developer of single-molecule diagnostics technology designed for the treatment of infectious diseases. The company's patented technology quickly detects proteins, DNA, and metabolites of interest in much smaller amounts than is possible with current methods and other bacterial strains that produce deadly Shiga toxin proteins, enabling physicians to detect biomarkers to identify potential cancers and infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Diagnostic Equipment
Primary Office
  • 15013 South
  • 24th Way
  • Phoenix, AZ 85048
  • United States
+1 (480) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Attometrics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 01-Jan-2016 $149K 0000 Completed Startup
1. Accelerator/Incubator 19-Nov-2012 0000 0000 Completed Startup
To view Attometrics’s complete valuation and funding history, request access »

Attometrics Executive Team (1)

Name Title Board Seat Contact Info
Wayne Frasch Founder & Chief Executive Officer
To view Attometrics’s complete executive team members history, request access »

Attometrics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
ASU Venture Catalyst Accelerator/Incubator Minority 000 0000 000000 0
To view Attometrics’s complete investors history, request access »